MK-0873

• Description :

  MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA) . Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) [1].

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/mk-0873.html

• Purity :

  95

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CN(C2=CC(C#CC3=C[N+]([O-])=CC=C3)=CC=C2)C4=NC=CC=C4C1=O)NC5CC5

• Molecular Formula :

  C25H18N4O3

• Molecular Weight :

  422.44

• References & Citations :

  [1]Boot J D, et al. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers[J]. Pulmonary Pharmacology & Therapeutics, 2008, 21 (3) : 573-577.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  PDE4

• CAS Number :

  [500355-52-2]